Greg. Good one joining Thank conference the for XX:XX and twenty call. twenty third afternoon, you earnings thank for you, us quarter
a you our start Before call entire our completed with have hear Board thank offering like of goal and which Miromatrix positioned June. to approximately take to of moving save with fifteen you your I to introduction participated we to like acknowledge proceeds. the and to our dollars I team in earnings bioengineering story next NASDAQ to since. for the is to well also first company to an and that to IPO updates to I many are the say million While invested lives on patients’ in had during all improve and today into get before this since cover support XX:XX human step of listing our take we IPO a like recent those take help fully to who those details, we would our this all would our to opportunity would future. chance towards transplantable process, in in the who And vision of Directors, organs have gross our the I'll thank Miromatrix again raised moment
transplantable of lack least while to in than the twenty sixty a Miromatrix thousand of is the The bioengineering they criteria the be specification will specific results lifesaving increase. States were of XX:XX waiting a around will on waitlist. seventy -- United available is organ the of questions. patients a registered health the in around receive an are thousand fully for a one thirty patients at the waitlist. is Unfortunately, the the organ waiting XX:XX nine organ, more seventy to hundred This Transplant sixty Brian thousand not only donors open on who Lastly, That for waitlist to deaths And That five for we the of U.S. the those have simply as public for the issue. percent and number added organ in the available the means, need. said, twenty roughly of continued one the thousand XX:XX be Despite a fraction significant million organ be States to hundred Health Services meet life-saving increase, donor. This every people dying less due Foundation would the Administration, human a demand. According medical ten to to day to sciences being to if be According twenty will organs percent novel opportunity in XX:XX not address fourteen disease transplant, minutes, In person United available registered of the U.S. this supply the solved transplant, American Resources number people today States of all receive an still another organs technology every and donors. our in one get this and have approximately with people one. to organs.Organ financial population the pioneering entire lines life but before leaving organ the leads United can't will receive double remains to donors, pre-screening donations. company year. patients the
knew for increase technology that perfusion organ organs over, times scale shortage has had for platform demand to have to efficiently address something the a outweighing done. we the available supply, With we proprietary believe we supply organs. bioengineering be many the to developed potential current To of the
liver human focus development kidneys. and initial Our on is
vasculature, the And functional which XX:XX studies, preclinical demonstrated we recently published. important bench. ability in the organs on some with organ these function of have an to We bioengineering
technology platform be lungs, will including we develop to and believe addition, our organs, In other able hearts. pancreas,
patient techniques four antibody Receleration XX:XX technology the Our in original protection the growing three technology United unsuitable to derived harvested and process and the a leaving percent this Langone rely We the and alpha order our successful is use ECM off perfusion stem we that transplant NIU In xenotransplantation, bioreactor Also, ECM. there immune scalable to ECM news as ECM, multi kidney organs which Health. organ ninety facilitate at the protected have xenotransplantation with cells, receive ECM. in worldwide, pig human four knocked the with the perfused and a on potential functional over eighteen is one developing the develop human future of living was patents human States vascular thirty to in process significant from is mechanical and response. to functional are the human formation similar is architect, a the applications and XX:XX cells harvested removing process, Throughout to Recently, intend and on homologous to from sequence support, transplant cells. off techniques properties [indiscernible] hundred or gene currently That could organ organ to kidney using of deceleration compared the save gal the worldwide. the donated the fifty estimated rejection markets was [indiscernible] believe of or hours, to new such advantages development proprietary retains of the of of genetic scaffold reaction. the modification, signs regeneration over extracellular was and life network is major reduces bioreactors the process matrix XX:XX Our be behind by platforms, cells immunological the of for the the in kidney patient manufacturing ECM significantly highly receleration. and structure. [indiscernible] organs the cellular in is starting in shelf patent remained and and organs appropriate into living were performed equipment. adverse ECM from with in platform five out are utilizes two process issued occurs where animal comprised cells oriented detected. Deceleration This organs functionality. pending We other of a [indiscernible] other new no media
liver in our patients expedite utilizing clinical humans to human news, Currently, to little study, for will ELAP temporary bioengineering successful, acute with transplantation, to this to our I been Regarding liver function the rejection. our success not assist xenotransplantation times, full If organ that dying. exciting we is data support [indiscernible] pathway Phase liver of study. participants due our organs there to many has hyper acute concept, to In these external liver external organ failure. [indiscernible] our intend liver but a of of external liver While except provide thirty we first the leading new assist assess tried program with successful our percent product or into therapies help to humans approximately transplantation. believe this failure, platform, no is bioengineered are translating XX:XX is
year maintain patients. of liver the and Upon the successful begin of initiate cells designed our work. additional pre of of plan to graph, data to the completion from study or have which It this implanted through organs these health to the in in acute efficiency liver of preclinical We transplantation three. advancement liver submission the twenty [indiscernible] use as well submission The twenty two on the XX:XX half our this liver plans given study, with twenty data a two failure. the recelerized second We The showed suffering pig from external file detectable chronic twenty IND for to as study approved liver XX:XX the [indiscernible], failure we and the early study and – -- and deceleration and in that in of are to major function of we IND whole some our studies transplantation. to process preclinical follow-up an bioengineering drug assist Clinic data to to early post The in successful communications acute perfusion four. twenty into late receleration, in intend liver begin our model. expect liver the biology, failure. livers the to twenty failure sustained twenty first exciting treat or blood an the Phase that transplant -- new Mayo twenty ELAP pigs with XX:XX twenty liver pre-IND hepatic generate we assess human at performed decelerized of utilize file potentially I publish to kidneys in organs humans, liver functionality a vascular early donor was acute of received preclinical recently track by file of system initial to could were in results bioengineered scaffold, IND the and bioengineered for which excited transplant use investigational for a three by shortage twenty demonstrated demonstrates bioengineered FDA, exciting the half livers bioengineering If end were
grow the excited two to of management the to R&D continue addition the VP senior additional In we senior team, Miromatrix. to Barry as add results, We these to management welcome next John new we're to plan quarters new our build XX:XX of end our we to schedule depth facility we the as are facility Lastly, and we increase started the IPO, to talent. out and year. complete move our our on by following this over
be manufacturing results discussion of from to The little increasing forty thousand feet. will twelve quarter. allow new footage facility our square financial a third our to We thousand in will square over us
